These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 2879302)

  • 1. Multiple forms of the D1 dopamine receptor: its linkage to adenylate cyclase and psychopharmacological effects.
    Mailman RB; Schulz DW; Kilts CD; Lewis MH; Rollema H; Wyrick S
    Psychopharmacol Bull; 1986; 22(3):593-8. PubMed ID: 2879302
    [No Abstract]   [Full Text] [Related]  

  • 2. Biochemical and behavioral studies of D1 dopamine receptors utilizing SCH 23390.
    Hess EJ; Creese I
    Psychopharmacol Bull; 1986; 22(3):605-12. PubMed ID: 2879304
    [No Abstract]   [Full Text] [Related]  

  • 3. Biochemical characteristics of D1 dopamine receptors: relationship to behavior and schizophrenia.
    Creese I; Hess EJ
    Clin Neuropharmacol; 1986; 9 Suppl 4():14-6. PubMed ID: 2882838
    [No Abstract]   [Full Text] [Related]  

  • 4. D1 dopamine receptor--the search for a function: a critical evaluation of the D1/D2 dopamine receptor classification and its functional implications.
    Clark D; White FJ
    Synapse; 1987; 1(4):347-88. PubMed ID: 2971273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological profile of SCH39166: a dopamine D1 selective benzonaphthazepine with potential antipsychotic activity.
    Chipkin RE; Iorio LC; Coffin VL; McQuade RD; Berger JG; Barnett A
    J Pharmacol Exp Ther; 1988 Dec; 247(3):1093-102. PubMed ID: 2905002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of D1 and D2 dopamine antagonists on heroin-trained drug discrimination.
    Corrigall WA; Coen KM
    NIDA Res Monogr; 1989; 95():499. PubMed ID: 2577048
    [No Abstract]   [Full Text] [Related]  

  • 7. Site-specific blockade of dopamine receptors by neuroleptic agents in human brain.
    Borison RL; Fields JZ; Diamond BI
    Neuropharmacology; 1981 Dec; 20(12B):1321-2. PubMed ID: 6119643
    [No Abstract]   [Full Text] [Related]  

  • 8. Effects of chronic SCH23390 treatment on the biochemical and behavioral properties of D1 and D2 dopamine receptors: potentiated behavioral responses to a D2 dopamine agonist after selective D1 dopamine receptor upregulation.
    Hess EJ; Albers LJ; Le H; Creese I
    J Pharmacol Exp Ther; 1986 Sep; 238(3):846-54. PubMed ID: 3018223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dopamine-sensitive adenylate cyclase and receptor binding activities after acute and chronic neuroleptic drug treatment.
    Clement-Cormier Y
    Adv Biochem Psychopharmacol; 1980; 24():103-11. PubMed ID: 6105768
    [No Abstract]   [Full Text] [Related]  

  • 10. Further evidence for the existence of multiple receptors for dopamine in the central nervous system.
    Iversen LL; Quik M; Emson PC; Dowling JE; Watling KJ
    Adv Biochem Psychopharmacol; 1980; 21():193-202. PubMed ID: 6103646
    [No Abstract]   [Full Text] [Related]  

  • 11. [Action of etmozin and ethacizin on dopaminergic adenylate cyclase of the striate system of the brain].
    Baldenkov GN; Ratner EI; Rozenshtraukh LV; Tkachuk VA
    Biull Eksp Biol Med; 1984 Oct; 98(10):448-50. PubMed ID: 6149776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SK&F 83822 distinguishes adenylyl cyclase from phospholipase C-coupled dopamine D1-like receptors: behavioural topography.
    O'Sullivan GJ; Roth BL; Kinsella A; Waddington JL
    Eur J Pharmacol; 2004 Feb; 486(3):273-80. PubMed ID: 14985049
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Central nervous system dopamine receptors.
    Creese I
    Adv Biochem Psychopharmacol; 1980; 21():235-42. PubMed ID: 6103649
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinical evidence for multiple dopamine receptors in man.
    Meltzer HY
    Commun Psychopharmacol; 1979; 3(6):457-70. PubMed ID: 44694
    [No Abstract]   [Full Text] [Related]  

  • 15. [Dependence of the antipsychotic effect of neuroleptics on their dopamine-blocking properties].
    Arushanian EB
    Farmakol Toksikol; 1982; 45(5):118-26. PubMed ID: 6128251
    [No Abstract]   [Full Text] [Related]  

  • 16. Dopamine-sensitive adenylate cyclase and dopamine/neuroleptic receptor binding: effect of neuroleptic drugs.
    Marshall AM; Mishra RK
    Adv Biochem Psychopharmacol; 1980; 24():153-7. PubMed ID: 6105772
    [No Abstract]   [Full Text] [Related]  

  • 17. Dopamine receptor pharmacology.
    Seeman P; Van Tol HH
    Curr Opin Neurol Neurosurg; 1993 Aug; 6(4):602-8. PubMed ID: 8104554
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of drugs and lesions on dopamine-stimulated adenylate cyclase: evidence for different classes of dopamine receptors.
    Katzman R; Makman MH; Ahn HS; Mishra RK; Gardner E
    Trans Am Neurol Assoc; 1977; 102():76-9. PubMed ID: 98893
    [No Abstract]   [Full Text] [Related]  

  • 19. Dopamine receptor changes in response to prolonged treatment with L-dopa.
    Groppetti A; Flauto C; Parati E; Vescovi A; Rusconi L; Parenti M
    J Neural Transm Suppl; 1986; 22():33-45. PubMed ID: 2946813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. No evidence for increased dopamine receptor binding in superresponsive mice after a single dose of neuroleptics.
    Hyttel J
    Adv Biochem Psychopharmacol; 1980; 24():167-73. PubMed ID: 6105773
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.